<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56931">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01793233</url>
  </required_header>
  <id_info>
    <org_study_id>ALTE11C1</org_study_id>
    <secondary_id>NCI-2013-00069</secondary_id>
    <secondary_id>COG-ALTE11C1</secondary_id>
    <nct_id>NCT01793233</nct_id>
  </id_info>
  <brief_title>Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas</brief_title>
  <official_title>Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies blood sample markers of reproductive hormones in assessing
      ovarian reserve in younger patients with newly diagnosed lymphomas. Studying samples of
      blood from patients with cancer in the laboratory may help measure the effect of curative
      therapy for lymphoma on ovarian failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are to compare Anti Mullerian Hormone (AMH), Follicle
      Stimulating Hormone (FSH), and Estradiol (E2) between patients (enrolled groupwide) at two
      timepoints (baseline and 12 months off therapy) and a cross section of controls (enrolled at
      limited institutions) and to describe the trajectory of AMH, FSH, and E2 from baseline to 12
      months after completion of gonadotoxic cancer treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Comparison of the measures of ovarian reserve (AMH, FSH and E2) to that of healthy controls</measure>
    <time_frame>12 months post therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared using the Wilcoxon rank-sum test or the two sample t-test after appropriate transformation. Analysis of covariance will be used to adjust these comparisons for covariates including age, race, dose of alkylating agent and use of hormone medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe acute ovarian failure (AOF) prevalence 12 months post-therapy</measure>
    <time_frame>12 months post therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Describe the rate of acute ovarian failure (amenorrhea plus FSH and E2) at 12 months post-therapy. With 195-205 enrolled case patients the uncertainty in the estimates of the ovarian failure rate at 12 months post-therapy would be at most Â± 5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of recovery of AMH, FSH, and E2 in the post-therapy phase</measure>
    <time_frame>12 months post therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Generalized estimating equation (GEE) will be used to model the change as a function of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of AOF</measure>
    <time_frame>12 months post therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Hodgkins Disease</condition>
  <arm_group>
    <arm_group_label>Health services research (menstrual diary, biomarker analysis)</arm_group_label>
    <description>Patients complete a menstrual diary to document vaginal bleeding (questionnaire administration), complete a medication log and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment for laboratory biomarker analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Health services research (menstrual diary, biomarker analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Health services research (menstrual diary, biomarker analysis)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collect blood samples for future evaluation of drug metabolizing enzyme polymorphisms.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female adolescents with Lymphoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have had first menses &lt;= 6 months prior to enrollment

          -  Patients must be newly diagnosed with lymphoma. This includes but is not limited to
             Hodgkin Lymphoma, Burkitts Lymphoma, Diffuse Large B Cell Lymphoma, and Anaplastic
             Large Cell Lymphoma.

          -  Planned cancer treatment must include an alkylating agent: ie procarbazine,
             cyclophosphamide, ifosphamide. Planned cancer treatment must be less than one year.

          -  Patients with any performance status are eligible for enrollment

          -  Patients may take oral contraceptives

        Exclusion Criteria:

          -  Patients who have previously received chemotherapy other than steroids

          -  Patients who have a secondary malignancy are not eligible

          -  Patients with known history of ovarian disease: e.g. Turner Syndrome or Polycystic
             Ovarian Syndrome

          -  Patients in whom planned therapy includes: removal or uterus or ovary(ies), pelvic
             irradiation, cranial irradiation or hematopoietic stem cell transplantation are not
             eligible

          -  Patients who previously have had their uterus or ovary(ies) removed are not eligible

          -  Patients who have received gonadotropin release hormone agonist or antagonist (e.g.
             Lupron) prior to study entry are not eligible

          -  Patients who are pregnant or breast feeding are not eligible

          -  Patients who have undergone or are planning to undergo ovarian tissue, oocyte or
             embryo cryopreservation prior to treatment are not eligible
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer M Levine, MD, MSW</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Levine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer M Levine, MD, MSW</last_name>
    <phone>212 305-5808</phone>
    <email>jl175@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M. Levine</last_name>
      <phone>212-305-5808</phone>
      <email>ji175@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer M. Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William D. Roberts</last_name>
      <phone>858-966-5934</phone>
    </contact>
    <investigator>
      <last_name>William D. Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Isakoff</last_name>
      <phone>860-545-9981</phone>
    </contact>
    <investigator>
      <last_name>Michael S. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher N. Frantz</last_name>
      <phone>302-651-5755</phone>
    </contact>
    <investigator>
      <last_name>Christopher N. Frantz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad K. Salman</last_name>
      <phone>239-343-5333</phone>
    </contact>
    <investigator>
      <last_name>Emad K. Salman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207-8426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Bradfield</last_name>
      <phone>904-697-3529</phone>
    </contact>
    <investigator>
      <last_name>Scott M. Bradfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <phone>407-650-7150</phone>
    </contact>
    <investigator>
      <last_name>Ramamoorthy Nagasubramanian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey H. Schwartz</last_name>
      <phone>904-697-3529</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey H. Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Hale</last_name>
      <phone>727-767-2423</phone>
      <email>HamblinF@allkids.org</email>
    </contact>
    <investigator>
      <last_name>Gregory A. Hale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marla H. Daves</last_name>
      <phone>404-778-1868</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Marla H. Daves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Fallon</last_name>
      <phone>317-274-2552</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Fallon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raymond Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <phone>515-241-6729</phone>
    </contact>
    <investigator>
      <last_name>Wendy L. Woods-Swafford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha F. Greenwood</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Martha F. Greenwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meret Henry</last_name>
      <phone>313-576-9363</phone>
    </contact>
    <investigator>
      <last_name>Meret Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Dickens</last_name>
      <phone>616-267-1925</phone>
    </contact>
    <investigator>
      <last_name>David S. Dickens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A. Ranalli</last_name>
      <phone>614-722-2708</phone>
    </contact>
    <investigator>
      <last_name>Mark A. Ranalli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill P. Ginsberg</last_name>
      <phone>215-590-2810</phone>
    </contact>
    <investigator>
      <last_name>Jill P. Ginsberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra L. Friedman</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Debra L. Friedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie R. Langevin</last_name>
      <phone>210-567-0653</phone>
      <email>che@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie R. Langevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle A. Yanofsky</last_name>
      <phone>866-561-1026</phone>
      <email>CIO_Web@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Rochelle A. Yanofsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana P. Silva</last_name>
      <phone>613-544-2630</phone>
    </contact>
    <investigator>
      <last_name>Mariana P. Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Hodgkins Lymphoma</keyword>
  <keyword>Hodgkins Disease</keyword>
  <keyword>Late Effects</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
